Enantone
PreclinicalSmall molecule
TakedaEnantone is one of 5 small molecule programs targeting Central precocious puberty. It is currently in Preclinical.
1
Indications
4
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Central Precocious Puberty
#DrugCompanyPhaseTrials
1Lupron
Sun Pharmaceutical Industries, Inc.Approved
Leuprorelin
TakedaPhase 3
Debio 025
DDebiopharm International SA
Phase 3
Gnrh Agonist
Johnson & JohnsonPreclinical
Enantone
TakedaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Central precocious puberty1 trial
Endometriosis1 trial
A Single-Center, Randomized, Open-Label, Phase Ia Trial Comparing the Pharmacokinetics/Pharmacodynamics, Safety, and Preliminary Efficacy of HHK001 and Enantone (Leuprorelin Acetate Microspheres for Injection) in Patients With Endometriosis
Not yet recruiting·TThe Third Xiangya Hospital of Central South University·Phase 1·NCT07793162·20 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Enantone. EMBL-EBI & Wellcome Sanger Institute.
- [4]